坦桑尼亚达累斯萨拉姆首次治疗肺结核患者肺功能异常的变化

IF 1.9 Q3 INFECTIOUS DISEASES

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Pub Date : 2025-05-30 DOI:10.1016/j.jctube.2025.100538

Reinhard Elisania Lema , Grace Ambrose Shayo , Zuhura Nkrumbih , Tumaini Joseph Nagu

{"title":"坦桑尼亚达累斯萨拉姆首次治疗肺结核患者肺功能异常的变化","authors":"Reinhard Elisania Lema , Grace Ambrose Shayo , Zuhura Nkrumbih , Tumaini Joseph Nagu","doi":"10.1016/j.jctube.2025.100538","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To document abnormalities in pulmonary function (PF) and associated factors in patients completing treatment for microbiologically confirmed, first-ever pulmonary tuberculosis (PTB).</div><div>From August 2020 to May 2021, we recruited 332 patients aged ≥15 years. PF was evaluated at baseline and at treatment completion. The Wilcoxon signed-rank test was used to compare median PF changes between baseline and treatment completion. A log-binomial regression model was used to determine factors associated with abnormal PF at treatment completion. Statistical significance was set at <em>p</em> ≤ 0.05.</div></div><div><h3>Results</h3><div>Abnormal PF was observed in 142 of 300 (47.3 %) patients who completed the study. Being male (RR [95 % CI] = 1.22 [1.19–2.23]), underweight (RR = 1.49 [1.13–1.95]), having lung cavitation (RR = 1.90 [1.29–2.78]), and lung fibrosis at baseline (RR = 2.16 [1.32–3.53]) were significantly associated with abnormal PF. The median (IQR) FEV<sub>1</sub> at treatment completion was 2.33 L (0.90–4.23 L) and FVC was 3.05 L (1.10–7.50 L), both significantly higher than FEV<sub>1</sub> of 2.18 L (0.20–5.70 L) and FVC of 2.82 L (0.26–7.05 L) at treatment initiation (<em>p</em> < 0.05 for both).</div></div><div><h3>Conclusion</h3><div>Approximately half of the patients had abnormal PF at treatment completion. Underweight patients, males, and those with lung cavitation at treatment initiation are more likely to have abnormal PF at the end of treatment and may require special attention.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100538"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Change in lung function abnormalities in patients treated for first ever pulmonary tuberculosis in Dar es Salaam, Tanzania\",\"authors\":\"Reinhard Elisania Lema , Grace Ambrose Shayo , Zuhura Nkrumbih , Tumaini Joseph Nagu\",\"doi\":\"10.1016/j.jctube.2025.100538\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>To document abnormalities in pulmonary function (PF) and associated factors in patients completing treatment for microbiologically confirmed, first-ever pulmonary tuberculosis (PTB).</div><div>From August 2020 to May 2021, we recruited 332 patients aged ≥15 years. PF was evaluated at baseline and at treatment completion. The Wilcoxon signed-rank test was used to compare median PF changes between baseline and treatment completion. A log-binomial regression model was used to determine factors associated with abnormal PF at treatment completion. Statistical significance was set at <em>p</em> ≤ 0.05.</div></div><div><h3>Results</h3><div>Abnormal PF was observed in 142 of 300 (47.3 %) patients who completed the study. Being male (RR [95 % CI] = 1.22 [1.19–2.23]), underweight (RR = 1.49 [1.13–1.95]), having lung cavitation (RR = 1.90 [1.29–2.78]), and lung fibrosis at baseline (RR = 2.16 [1.32–3.53]) were significantly associated with abnormal PF. The median (IQR) FEV<sub>1</sub> at treatment completion was 2.33 L (0.90–4.23 L) and FVC was 3.05 L (1.10–7.50 L), both significantly higher than FEV<sub>1</sub> of 2.18 L (0.20–5.70 L) and FVC of 2.82 L (0.26–7.05 L) at treatment initiation (<em>p</em> < 0.05 for both).</div></div><div><h3>Conclusion</h3><div>Approximately half of the patients had abnormal PF at treatment completion. Underweight patients, males, and those with lung cavitation at treatment initiation are more likely to have abnormal PF at the end of treatment and may require special attention.</div></div>\",\"PeriodicalId\":37942,\"journal\":{\"name\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"volume\":\"40 \",\"pages\":\"Article 100538\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405579425000294\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579425000294","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的记录微生物学证实的首次肺结核（PTB）患者完成治疗后肺功能（PF）及其相关因素的异常。从2020年8月到2021年5月，我们招募了332名年龄≥15岁的患者。在基线和治疗完成时评估PF。使用Wilcoxon符号秩检验比较基线和治疗完成之间的中位PF变化。采用对数二项回归模型确定与治疗结束时异常PF相关的因素。p≤0.05为差异有统计学意义。结果300例患者中有142例（47.3%）出现PF异常。男性（RR [95% CI] = 1.22[1.19-2.23]）、体重不足（RR = 1.49[1.13-1.95]）、肺空化（RR = 1.90[1.29-2.78]）、基线时肺纤维化（RR = 2.16[1.32-3.53]）与PF异常相关。治疗结束时FEV1的中位数（IQR）为2.33 L (0.90-4.23 L)， FVC为3.05 L (1.10-7.50 L)，均显著高于治疗开始时FEV1的2.18 L （0.20-5.70 L）和FVC的2.82 L (0.26-7.05 L) (p <；两者均为0.05)。结论约半数患者在治疗结束时出现PF异常。体重过轻的患者、男性和在治疗开始时出现肺空化的患者在治疗结束时更有可能出现异常的PF，可能需要特别注意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Change in lung function abnormalities in patients treated for first ever pulmonary tuberculosis in Dar es Salaam, Tanzania

Objectives

To document abnormalities in pulmonary function (PF) and associated factors in patients completing treatment for microbiologically confirmed, first-ever pulmonary tuberculosis (PTB).

From August 2020 to May 2021, we recruited 332 patients aged ≥15 years. PF was evaluated at baseline and at treatment completion. The Wilcoxon signed-rank test was used to compare median PF changes between baseline and treatment completion. A log-binomial regression model was used to determine factors associated with abnormal PF at treatment completion. Statistical significance was set at p ≤ 0.05.

Results

Abnormal PF was observed in 142 of 300 (47.3 %) patients who completed the study. Being male (RR [95 % CI] = 1.22 [1.19–2.23]), underweight (RR = 1.49 [1.13–1.95]), having lung cavitation (RR = 1.90 [1.29–2.78]), and lung fibrosis at baseline (RR = 2.16 [1.32–3.53]) were significantly associated with abnormal PF. The median (IQR) FEV₁ at treatment completion was 2.33 L (0.90–4.23 L) and FVC was 3.05 L (1.10–7.50 L), both significantly higher than FEV₁ of 2.18 L (0.20–5.70 L) and FVC of 2.82 L (0.26–7.05 L) at treatment initiation (p < 0.05 for both).

Conclusion

Approximately half of the patients had abnormal PF at treatment completion. Underweight patients, males, and those with lung cavitation at treatment initiation are more likely to have abnormal PF at the end of treatment and may require special attention.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.00

自引率

5.00%

发文量

审稿时长

30 weeks

期刊介绍： Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.